The European Medicines Agency is inviting comments on its draft transparency policy until 25 September 2009. Since its inauguration in 1995, the Agency has worked continuously to improve the transparency of its operations, often extending the levels of transparency beyond the existing legal requirements. Bringing together all these initiatives, the new draft transparency policy describes for the first time in one comprehensive document the Agency's vision on its level of openness towards its stakeholders.
Who Voted for this Story
Comments